My latest clinical pipeline column for @NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular #lymphoma.

#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment

https://www.nature.com/articles/d41591-023-00010-0